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Abstract: The first part of the article dealt with the basic science behind the evolution of ventricular restoration 
procedures and the rationale for the use of novel surgical techniques. The second part describes the preoperative workup 
of patients in advanced heart failure, the core information required to determine the surgical approach and the essential 
principles and techniques of ventricular restoration. It then examines the effects of ventricular restorative procedures on 
pump function and clinical outcomes, the results of the worldwide experience with ventricular restoration and concludes 
with more recent advances in this field.  
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1. PREOPERATIVE WORKUP 
  A comprehensive preoperative evaluation for surgical 
planning includes: (a) measurement of the asynergic 
(noncontracting) area of the scar, which is the nidus for 
remote dilation, (b) determination of the adequacy of remote 
muscle to support the circulation after scar exclusion, (c) 
ventricular volumes and indices, (d) viability of the surgical 
target and the remote muscle, (e) regional and global 
function, (e) mitral annular dilation, (f) interpapillary muscle 
width and (g) quantitative assessment of wall motion by 
tagging. Cardiac magnetic resonance imaging (MRI) allows 
a complete evaluation of these quantities [1]. 
1.  The scar is the nidus for subsequent dilation of remote 
muscle and asynergy >35% of the ventricular 
perimeter by ventriculography generally causes LV 
dilatation. Contiguous asynergy > 25% is amenable to 
SVR. The region to be surgically excluded is 
evaluated for wall motion and thickening. Late 
contrast enhancement helps characterize both 
infarcted and remote muscle. The region of asynergy 
whether dyskinetic or akinetic lacks contractility. 
Viability of the asynergic region (<50% transmural 
late enhancement) predicts functional recovery with 
revascularization alone, while predominant non-
viability (>50% enhancement) may preclude contrac-
tile recovery following revascularization alone. SVR 
excludes this nidus for dilation and reduces LV 
volume in such cases.  
2.  Tagging labels a specific volume of tissue whose 
motion is tracked through the cardiac cycle. Local 
myocardial contractility can be determined by the 
distortion of the tagged element boundaries. This is 
useful when a region of viable, contractile   
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  myocardium is adjacent to and tethers a region of 
nonviable, noncontracting muscle, thereby making the 
nonviable region appear contractile. Tagging clarifies 
this issue, since a viable, contracting segment exhibits 
‘squeezing’ deformation of tagged tissue, while a 
nonviable segment that is tethered shows a 
‘stretching’ deformation.  
3.  Remote muscle function provides the compensatory 
element for survival. Documentation of remote 
muscle contractility, or its viability if hypokinetic 
predicts functional recovery after SVR. The remote 
myocardium could be normal, infarcted, stunned or 
hibernating. Hibernating muscle (due to right or 
circumflex coronary stenoses), if inadequately 
revacularized, may lead to pump failure after SVR, if 
contractility is inadequate to support circulatory 
needs.Scarring of remote myocardium determines 
prognosis and is critical in patient selection. Remote 
muscle viability helps decide if revascularization of 
the circumflex or right coronaries is likely to be 
beneficial, as extensive scarring may preclude 
contractile recovery.  
4.  Viability analysis by MRI includes assessment of 
regional function and morphology. Myocardium with 
diastolic wall thickness < 5.5 mm may be nonviable.  
2. SVR PRINCIPLES 
  The fundamental principle of SVR is to exclude dead 
muscle and revascularize damaged remote muscle. This 
restores contractile capacity of the dilated hibernated remote 
muscle, which compresses the intraventricular patch, thereby 
improving mechanical performance. Evidence of patch 
movement has been observed by echocardiography and 
colour kinetics. The patch acts as an active endocardium and 
no significant dysfunctional zone is evident. LAD grafting is 
important to revascularize the upper septum. RCA/LCX 
grafting is crucial to revascularize the remote muscle which 
provides postoperative pump function [2].  
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3. SURGICAL TECHNIQUE 
  The concept of SVR consists of complete revas-
cularization to relieve ischemia, ventricular reconstruction to 
restore elliptical shape, reduction of volume and wall stress 
to improve hemodynamics and when necessary, endocar-
dectomy and cryoablation for VT [3-5]. Mitral valve repair is 
performed as needed.  
Operative Procedure 
  Following initiation of cardiopulmonary bypass and 
cardioplegic arrest, coronary revascularization and mitral 
repair are performed as necessary. With fibrotic, dyskinetic 
LVA, there is a clear transitional zone between dysfunctional 
tissue and viable contracting myocardium. Traditionally a 
linear repair technique has been used on thin-walled left 
ventricular aneurysms but this does not allow for septal 
exclusion. Lundblad [6] demonstrated that surgical risk is 
lower and long
 term survival is higher after endoventricular 
circular patch plasty [EVCPP] than simple linear repair.  
   The LV is opened through the infarcted, scarred area, 
which often collapses on cardiopulmonary bypass and 
venting. The ventriculotomy is extended parallel to the LAD. 
Clots are removed. A subtotal nonguided endocardectomy is 
performed on the septum and anterior wall if spontaneous or 
inducible VT exists. Linear cryo lesions are applied at the 
edge of the endocardial resection.  
  Akinetic areas must be recognized. With post-MI 
revascularization, the classic myocardial scar that collapses 
on venting may not be evident. It is important to exclude the 
entire segment to delete the midmyocardial and endocardial 
scar.  
  SVR can be performed on an arrested or beating heart. 
SVR on a beating heart has distinct advantages in thick 
walled akinetic ventricles where visual demarcation between 
scar and healthy muscle is not obvious.  
  Menicanti [7] introduced the use of a mannequin filled at 
50 to 60 ml/m
2 to optimize size and shape of the new 
ventricle. The mannequin is useful when the ventricle is not 
much dilated (to reduce the risk of a small residual cavity) or 
when the infarct is not clearly demarcated. Mannequins 
therefore prevent excessive reduction of ventricular volume, 
help position the new apex, create an elliptical shape and 
provide adequate volume reduction in huge ventricles where 
the scar is not readily apparent. Creation of a small LV 
results in a low cardiac output state, while a residual box like 
LV is characterized by diastolic dysfunction. Residual 
sphericity causes papillary muscle malalignment and MR.  
  An endoventricular circular suture (Fontan stitch) is 
placed at the transitional zone starting from the new apex, 
going medially
  toward the septum, superiorly toward the 
aortic valve, laterally
  toward the base of the papillary 
muscles and ending at the
 level of the apical reference stitch. 
The Fontan stitch is tightened to approximate the ventricular 
wall to the balloon. 
  A Dacron or pericardial patch is sewn to the ridge created 
by the purse-string suture. The ventriculotomy is then folded 
over the patch and closed. Patients are weaned from 
cardiopulmonary bypass with inotropes and/or an intraaortic 
balloon pump (IABP) as necessary.  
  Retention of spherical shape may persist when patch 
placement is limited to the scar, since extensively stretched 
remote muscle stretch is retained. This results in a spherical 
LV, with a box like apex on post-operative angiograms. This 
is the pitfall of using the scar as the guide in grossly dilated 
ventricles.  
  The SAVE or Pacopexy procedure [8] was initially 
developed for non-ischemic cardiomyopathy and is based on 
selecting the site for muscle resection depending on 
intraoperative echo findings, since muscle involvement is 
heterogenous. It was developed to reconstruct elliptical form, 
with patch placement in an oblique direction between the 
apex and the septum just below the aortic valve [9]. Patch 
placement differs from the Dor procedure where the scar 
defines patch placement.  
3A. Akinesia vs. Dyskinesia 
 Di  Donato  et al. demonstrated that outcome is more 
strongly linked to the extent of asynergy than to the type of 
asynergy (akinetic vs dyskinetic) [10]. Once the infarcted 
scar exceeds 20% of the LV surface area, cardiac function 
declines. Both dyskinetic and akinetic scars share similar 
mechanical defects.  
3B. Site Selection 
  In advanced idiopathic dilated cardiomyopathy, the 
extent of interstitial fibrosis is heterogenous. The choice of 
procedure is assessed by preoperative echocardiography, 
cardiac MRI and an intraoperative volume reduction test to 
find the weakest area.  
  The intraoperative echocardiography-guided volume 
reduction test helps detect changes in wall motion and 
thickness, when the dilated LV is decompressed on bypass, 
with a consequent reduction in wall tension [11]. The SAVE 
procedure [Pacopexy] is performed to exclude a weak 
septum. PLV, as described by Batista is used with 
predominant lateral wall involvement  
  Consequently, the intraventricular guideposts for recon-
struction that usually involves patch placement may alter 
from current attention that is directed only at the visible scar 
to the creation of a more natural form that may place sutures 
beyond the obvious disease.  
4. MITRAL INVOLVEMENT 
  Functional MR results from LV dysfunction and remo-
delling, LV sphericity, incomplete leaflet closure, papillary 
muscle displacement and systolic valvular tenting. MR 
portends a worse prognosis and overestimates remote muscle 
function. The dysfunctional LV is intolerant of any degree of 
MR greater than moderate.  
  Local deformation of the inferior wall with loss of 
systolic inward bending is associated with functional MR. 
End-systolic inferior wall curvature is a key determinant of 
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negative curvature (i.e., convex toward LV cavity), the 
mitral leaflets coapt normally. If the curvature is not negative 
(i.e., flat or concave), mitral tenting ensues. The inferolateral 
wall is the continuity between the basal loop and the 
descending segment of the ascending loop and explains the 
functional impairment of a region remote from the ischemic 
damage. Asynergy and systolic deformation of the infero-
basal region and high capillary wedge pressure are 
prognostic signs of MR development late after endoventri-
cular circular patch plasty repair [12].  
  Mitral annuloplasty with an undersized ring was 
proposed by Bolling [13]. Undersizing mitral annuloplasty 
has shown favorable results because of its low operative risk 
with symptomatic relief but its effect on longevity is 
controversial [13]. Patients with dilated ventricles show poor 
outcomes after mitral reconstruction alone, demonstrating 
the need for ventricular reduction.  
  The amelioration of mild mitral insufficiency after the 
Dor procedure relates to the restoration of LV ventricular 
geometry which results in a narrower configuration of 
papillary muscles. Improvement in functional MR is 
observed in 64% of patients despite no mitral intervention.  
  The presence of moderate-to-severe MR and its surgical 
repair carries a higher operative risk. MR becomes a true 
predictor of hospital mortality only when the LV end-
diastolic pressure, and therefore the left atrial pressure are 
severely increased, leading to CHF and severe functional 
impairment (NYHA class III/IV).  
  When the degree of MR is moderate to severe or the
 
annulus is dilated and ventricular function is
  severely 
depressed, the mitral valve should be preferably repaired 
during the SVR procedure.
 Di Donato and colleagues [10] 
demonstrated that late MR after the Dor procedure is 
associated with poor prognosis and emphasized early 
(intraoperative) correction. 
  Paradoxically, in a substantial number of patients without 
MR preoperatively, MR develops 1 year later. To prevent the 
risk of late MR, a more than 30ml/ m
2 reduction of end-
diastolic volume index should be avoided. Patients with late 
MR generally have greater preoperative volumes than did 
patients without late MR.  
5. SVR AND VENTRICULAR TACHYCARDIA 
  Sustained VT is associated with increased mortality in 
ischemic cardiomyopathy. Monomorphic premature ven-
tricular contractions originating from the scar border zone 
can be triggers for ventricular fibrillation. Coronary artery 
bypass graft surgery alone does not eliminate the risk of 
ventricular arrhythmias [14]. In 1994, Dor and associates 
presented an addition to the original endoventricular circular 
patch plasty, for patients with VT and a success rate 
exceeding 90% in curing VT was achieved [4]. The Dor 
procedure eliminates the need for an implantable defibrillator 
in most patients. However in cases with postoperative VT, 
an ICD is recommended.  
  Mapping studies by Mickleborough [15] in patients with 
recurrent VT showed that ease of arrhythmia induction was 
related to mechanical loading conditions. Myocardial stretch 
is arrhythmogenic. Late recurrences of ventricular arrhy-
thmias after LV reconstruction might be due to progressive 
remodeling and LV enlargement.  
6. THE EFFECTS OF SVR  
  SVR alters ventricular shape and volume, improves 
survival, functional class, and ejection fraction [3, 10, 16] 
and can achieve a high degree of freedom from re-admission 
for heart failure. It creates a mechanical intraventricular 
resynchronization in patients without conduction delay, 
which improves LV performance and may reduce ventricular 
arrhythmias in the dilated heart [17]. Recent reports [18] 
indicate a higher mortality when preoperative LVESVI > 
120 ml/m
2 as a larger chamber is left if exclusion is limited 
to the edge of the scar.  
  Tulner and colleagues [19] used conductance catheters to 
show that SVR normalized left ventricular volumes, reduced 
left ventricular wall stress and oxygen consumption and 
improved wall compliance and mechanical efficiency.  
6A. Effect on Systolic Function 
  The relatively small changes in systolic function in 
patients who had isolated restrictive mitral annuloplasty or 
CABG indicate that the systolic improvements following 
SVR are mainly related to LV restoration. The increase in 
EF is attributed to a reduction in end-diastolic volume, as LV 
stroke volume is unchanged. However, EF is an inaccurate 
index of systolic performance after SVR due to altered post-
operative loading conditions. The slope of the end-systolic 
pressure-volume relation, end-systolic elastance EES, is a 
load-independent index of systolic function and improves 
significantly after SVR. Schreuder [20] used cardiac catheter 
data to document an improvement in EES after the DOR 
procedure. This improvement is induced by exclusion of a 
large compliant scar, and recruitment of remote myocardium.  
6B. Effect on Diastolic Function 
  Resection of a portion of the LV wall can detrimentally 
affect diastolic chamber properties and (2) the effect of such 
a procedure on overall pump function reflects the balance of 
its effects on systolic and diastolic properties [21]. The 
effects on diastolic function are more controversial and 
complex to interpret. The relaxation time constant  is 
significantly reduced, indicating faster relaxation. This time-
constant quantifies the speed of LV pressure decay during 
isovolumic relaxation [19]. This change may result from 
coronary revascularization—which may enhance the oxygen-
dependent reuptake process of calcium by the sarcoplasmic 
reticulum or from an afterload reduction as active relaxation 
is afterload dependent.  
  The LV relaxation indices dP/dtmax and  are generally 
decreased and prolonged respectively, in congestive heart 
failure and in LV aneurysm, which indicates LV mechani- 
cal dyssynchrony in early diastole [22]. After patch 
aneurysmectomy dP/dtmax was lower and  was markedly 
reduced, indicating an improvement in LV relaxation during 
early diastole. Overall LV diastolic function however   
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appeared to be compromised. The diastolic pressure-volume 
relation was significantly shifted toward smaller volumes 
and tended to be steeper, as evidenced by an increased 
diastolic stiffness constant.  
6C. Effect on Work  
  SVR induces a leftward shift of both the end-systolic and 
the end-diastolic pressure-volume relations. Stroke work and 
cardiac output are maintained but at the expense of a higher 
end-diastolic pressure after SVR, indicating reduced reserves 
to further augment stoke work by the Frank-Starling 
mechanism [19]. Recurrent LV remodelling can occur 
especially in patients with a larger preoperative LVESVI.  
6D. Effects on BNP 
  Brian natriuretic peptide [BNP] is a hormone released 
from the ventricles in response to wall stress and ischemia. 
SVR induces a persistent reduction of NT-pro-BNP and BNP 
6 months postoperatively and at late follow-up respectively. 
Increasing ejection fraction and decreasing LVESV 
correlated significantly with lower BNP and NT-pro-BNP 
levels 6 months after surgery [23]. No significant linear 
association between peptide levels and ejection fraction or 
LV volumes was found at baseline.  
7. CAUSES FOR FAILURE 
  The return of heart failure after the surgery is attributed 
to (1) recurrent MR, (2) continued LV remodelling; (3) too 
small a LV caused by excessive excision, (4) removal of the 
kinetic area while retaining poorly contractile and more 
fibrotic regions, (5) evolution of coronary artery disease or 
repeated ischemic episodes and (6) improper identification 
of the transition between scar and normal muscle in akinetic 
regions, leading to possible salvage of an excess of scarred 
ventricle. 
8. SVR DATA 
  Maxey [24] and Ribeiro [25] showed that outcomes 
following CABG + SVR were superior to CABG alone in 
patients with ischemic cardiomyopathy. Most reported 
studies are not randomized and the question as to whether 
adding SVR to coronary artery bypass grafting (CABG) will 
improve survival and clinical status will be answered by the 
ongoing Surgical Treatment of Ischemic Heart failure Trial 
[STICH trial] [26]. 
9. STICH TRIAL  
  The STICH trial will address the management of patients 
with heart failure who have CAD amenable to revascu-
larization. This is a prospective randomized study with 2800 
patients from 100 centres. Patients with left ventricular 
dysfunction and coronary artery disease amenable to CABG 
will be randomized to combinations of three different 
treatment strategies: CABG, SVR, and intensive medical 
therapy (MED).  
(a)  The revascularization hypothesis states that coronary 
artery bypass grafting (CABG) with intensive medical 
therapy (MED) improves long-term survival com-
pared to MED alone. 
(b)  The reconstruction hypothesis states that in patients 
with anterior LV dysfunction, surgical ventricular 
restoration (SVR) to a more normal LV size improves 
survival free of subsequent hospitalization for cardiac 
cause in comparison to CABG alone. 
  When compared with MED alone, CABG is expected to 
confer a 20% reduction in mortality. These data are expected 
to solidify the role of bypass surgery in the treatment of 
ICMPY. Ventricular restoration is also expected to improve 
hospitalization-free survival by 20% when compared with 
CABG alone. This will also serve to dramatically improve 
outcomes in a patient population that has a 50% 3-year 
survival rate without SVR.  
  The STICH protocol uses LVESVI measurement to make 
decisions about placing patients into the 3 study groups. If 
LVESVI is less than 60 ml/m
2, the intervention decision 
relates to comparing the effects of either using medical 
treatment or adding CABG. When LVESVI > 60 ml/m
2, the 
decision question relates to how SVR fits into the treatment 
scheme in 1200 patients.  
10. RESULTS  
  Contemporary results following SVR and the risk factors 
for mortality are included in Table 1. An analysis of the use 
and outcomes of SVR in a national sample in a real world 
application reveals that perioperative events are somewhat 
higher than prior selected series.  
  The performance of SVR in patients after a recent MI or 
in an emergent setting is contrary to what was done in 
RESTORE group, where the surgery was performed an 
average of 4.4 years after an anterior infarct. However, Di 
Donato et al. [27] have demonstrated an operative mortality 
of 5.4% in 74 patients with an SVR performed within 30 
days from an anterior infarct [16]. The patients in the Di 
Donato et al study did not wait the typical 3 months for SVR 
that is standard at their center because of angina, NYHA 
class IV symptoms, heart failure, arrhythmias and cardio-
genic shock. Performing SVR after a recent MI, makes it 
difficult to appreciate the limits of remodelling, but provides 
the benefit of early revascularization and the early exclusion 
of akinetic myocardium thereby avoiding subsequent 
remodelling. Conte et al. showed excellent functional 
outcomes in such patients, with nearly  of the patients 
improving from NYHA class III/IV to NYHA class I or II 
following surgery.  
11. RECENT ADVANCES AND CONCLUSION 
  The effects of shape restoration may be combined with 
cell implantation into remote muscle [28] to enhance 
recovery of retained diseased muscle. Heart failure 
secondary to post-infarction left ventricular remodeling can 
be reversed by SVR. Surgical ventricular restoration by the 
Dor procedure can achieve good long-term survival and a 
high degree of freedom from readmission for heart failure in 
patients with advanced ischemic heart disease.  354    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Shanmugam and Ali 
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ABBREVIATIONS  
AII =  Angiotensin  II 
BNP  =  Brain natriuretic peptide 
CABG  =  Coronary artery bypass grafting 
CAD  =  Coronary artery disease 
CHF  =  Congestive heart failure 
HF =  Heart  failure 
ICMPY =  Ischemic  cardiomyopathy 
IHD  =  Ischemic heart disease 
EF   =  Ejection fraction 
EVCPP  =  Endoventricular circular patch plasty 
DCM =  Dilated  cardiomyopathy 
GUSTO  =  Global Utilization of Streptokinase  
Trial     and Tissue Plasminogen Activator for  
   Occluded  Coronary  Arteries 
IABP  =  Intra aortic balloon pump 
ICD =  Implantable  cardioverter  defibrillator 
LAD   =  Left anterior descending artery 
LCX  =  Left circumflex artery 
LV   =  Left Ventricle 
LMI  =  Lateral wall myocardial infarction 
LVA  =  Left ventricular aneurysm 
LVESVI  =  Left ventricular end systolic volume  
   index 
LVESV  =  Left ventricular end systolic volume  
MI   =  Myocardial infarction 
MR   =  Mitral regurgitation 
MRI  =  Magnetic resonance imaging 
NE =  Norepinephrine 
NT-pro-BNP  =  N-terminal portion of proBNP 
NYHA  =  New york heart association 
PHTN   =  Pulmonary hypertension 
PLV =  Partial  left  ventriculectomy 
PRA  =  Plasma renin assay 
PTCA  =  Percutaneous transluminal coronary  
   angioplasty 
REMATCH   =  Randomized evaluation of mechanical  
    assistance for the treatment of  
    congestive heart failure 
RESTORE  =  Reconstructive Endoventricular Surgery  
Trial     returning Torsion Original Radius  
    Elliptical shape to the left ventricle 
RCA =  Right  coronary  artery 
RV =  Right  Ventricle 
SAVE  =  Septal Anterior Ventricular Exclusion 
procedure 
SAVE trial   =  Survival and ventricular enlargement 
STICH   =  Surgical treatment for ischemic heart  
   failure 
SVR   =  Surgical ventricular restoration 
VT =  Ventricular  tachycardia 
TOAT =  Open  artery  trial 
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